Prime Medicine, Inc.
NASDAQPrime Medicine enters the week in an unusual spot for a heavily shorted biotech — the stock is up 8% on the week and 30% over the past month, while bears have been quietly adding to already elevated positions. The short interest story here is genuinely extreme. Nearly 19% of the free float is sold short — around 33.6 million shares — and that figure has climbed 8% over the past…
PRME SI utilization hits 93.64%, nearing 52-week high of 100% — borrowing demand intense amid 19% short interest of free float.
Snapshot as of 12 Jul 2026
Prime Medicine enters the week in an unusual spot for a heavily shorted biotech — the stock is up 8% on the week and 30% over the past month, while bears have been quietly adding to already elevated positions. The…
PRME heads into its June 5 earnings call with short positioning at its most crowded level in months and the borrow market tightening sharply — a setup that puts maximum pressure on whatever the company delivers next…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PRME — free to start on ORTEX.
Sign up for free →Open PRME on ORTEX